Carboprost Tromethamine Market Size, Share & Trends Analysis Report By Application (Postpartum Hemorrhage Treatment, Pregnancy Abortion), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Carboprost Tromethamine Market Trends

The global carboprost tromethamine market size is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2030. The growing prevalence of postpartum uterine hemorrhage and abortion has created immense opportunities for key market players. In addition, other factors driving the market growth are the rising pregnancy rate, growing patient awareness for treatment, increased supply and distribution of drugs, and increasing FDA approval.Carboprost tromethamine is a prostaglandin used to treat postpartum uterine hemorrhage and abortion. The use of carboprost tromethamine prevents high-risk postpartum hemorrhage in pregnant women, reducing the level of bleeding and promoting recovery of coagulation function. For instance, in May 2023, Eugia U.S. announced the U.S. FDA approval for the production and marketing of carboprost tromethamine injection USP 250 mcg/mL, Single-Dose Vials. The injection is used for aborting between the 13th and 20th weeks of gestation and in conditions abortion-related in the second trimester.

Moreover, postpartum hemorrhage is the leading cause of maternal death across the globe. According to WHO, in February 2023, there has been an increase in maternal mortality. Besides, around 95% of all maternal deaths occurred in low and lower-middle-income countries. The rising number of maternal deaths and postpartum incidences has led to rising demand for the carboprost tromethamine market.The COVID-19 pandemic significantly impacted the carboprost tromethamine market. The pandemic initially disrupted global supply chains to some extent, affecting distribution of products in hospital pharmacies and retail pharmacies, which led to shortages in the market.

Application Insights

On the basis of application, the carboprost tromethamine market is segmented into postpartum hemorrhage treatment and pregnancy abortion. Postpartum Hemorrhage (PPH) held the largest market share in 2023. The growth of this segment is majorly driven by the prevalence of postpartum hemorrhage, the growing number of pregnancies, and the increasing number of deliveries across the globe. Globally, postpartum hemorrhage is the leading cause of maternal mortality. For instance, according to WHO, around 14 million women experience PPH, resulting in about 70,000 maternal deaths every year across the globe. In addition, surviving women need surgical interventions to control the bleeding and are left with life-long reproductive disability. Thereby, carboprost tromethamine products support women during childbirth, reducing maternal mortality. Carboprost tromethamine (prostaglandin) effectively reduces contraction of the uterus and the amount of bleeding during & after delivery. Such factors drive the segment growth. Likewise, the rising number of abortions has increased the market revenue. For instance, according to WHO, around 73 million women globally opt for abortion each year. In addition, out of all unintended pregnancies, 6 out of 10 (61%) end in abortion, and 3 out of 10 (29%) of all pregnancies end in abortion.

Distribution Channel Insights

On the basis of distribution channels, the market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. Hospital pharmacies dominated the market in 2023. The growing availability of drugs across hospital pharmacies is expected to fuel the market growth. This factor provides new opportunities for hospital pharmacies to assist with risk prevention strategies, emergency management of the PPH patient, assessment of pharmacotherapy, sterile product preparation, and prevention of medication errors.

Furthermore, growing product innovation is expected to propel the market growth. For instance, in February 2022, Amneal Pharmaceuticals, Inc. announced the approval of carboprost tromethamine injection, a generic injectable product. The injection is USP 250 mcg/mL and has received Abbreviated New Drug Application (ANDA) approval from the U.S. FDA. Thus, the segment is expected to witness growth.

Regional Insights

North America dominated the market in 2023, which can be attributed to the growing prevalence of postpartum hemorrhage, rising pregnancy rate, increasing number of childbirths, a growing number of unplanned pregnancies, and rising abortion rate that has led to a rise in demand for carboprost tromethamine across the region. For instance, in 2021, the CDC mentioned the number of births in the U.S. was 3,664,292, and the birth rate was 11.0 per 1,000 population. This factor has led to a rise in the incidence of postpartum hemorrhage and demand for treatments. Some other factors contributing to the market growth are growing awareness of treatment, the presence of well-established market players, and the rising number of approvals for carboprost tromethamine.

Key Companies & Market Share Insights

Some of the key players operating in the market are Amneal Pharmaceuticals LLP; ChemScene; Dr. Reddy's Laboratories Ltd.; Merck KGaA; Pfizer; Universal Biologicals; Woodward Pharma; BioSpectra, Inc.; ANGUS Chemical Company; MANUS AKTTEVA BIOPHARMA LLP; Biosynth; Monvi labs; Taj Pharmaceuticals Limited; Bio-Techne; SimSon Pharma Limited; Watson International Limited; Ryvis Pharma; and Apionex Pharma Pvt Ltd.

The key players in the market undertake various strategic initiatives, such as new FDA approval, product launches, partnerships, and mergers & acquisitions, to gain more market share. For instance, in February 2023, the U.S. FDA granted approval to Caplin Point Laboratories Ltd for its ANDA carboprost tromethamine injection USP (250 mcg/mL). It is a generic single-dose vial equivalent therapeutic version of Pfizer Inc’s (RLD), HEMABATE Injection. It is oxytocic for treating postpartum hemorrhage caused by uterine atony.